Abstract 797P
Background
EMA-CO is the most used combined chemotherapy regimen for treating high-risk gestational trophoblastic neoplasia (GTN) patients. It is administered weekly until normalization of hCG levels, followed by two consolidation cycles. Premature discontinuation of EMA-CO chemotherapy due to dose-limiting toxicities may occur before achieving the target hCG threshold. Despite its widespread use, the effectiveness of consolidation cycles in preventing recurrence in GTN patients remains unclear. In this study, we aimed to evaluate the impact of EMA-CO consolidation cycles on recurrence.
Methods
We conducted a non-interventional, retrospective study in patients selected from the French Center for Trophoblastic Diseases in Lyon and identified 276 patients with a GTN diagnosis and treated with EMA-CO regimen between November 1999 and November 2020 from our database. Exclusion criteria for this study included resistance to EMA-CO chemotherapy (n=31). We assessed the impact of two cycles of EMA-CO consolidation on the 2-year recurrence-free survival (RFS).
Results
A total of 245 patients met the eligibility criteria for this study, of whom 88.6% (217/245) received consolidation cycles of EMA-CO. Choriocarcinomas were diagnosed in 42% (102/245) of the patients, while invasive mole was observed in 58% (143/245) of cases. The median FIGO score was 8 (range 1 – 19). After a median follow-up of 23 months, the 2-year RFS was 93% (95%CI 0.90 to 0.96) in the consolidation group and 90% (95% CI 0.79 to 1.0) in the group of patients who didn’t receive consolidation cycles (HR 0.79; 95% CI 0.23 to 2.72, p=0.71). Grade ≥ 2 adverse events occurred in 43% of patients, with neutropenia being the most frequent (31%).
Conclusions
In this study, the 2-year RFS was not significantly different between the groups. These findings suggest that consolidation cycles may not influence recurrence in patients with gestational trophoblastic neoplasia. Considering the non-negligible toxicity of EMA-CO, our results raise the question of optimizing therapy through de-escalation and/or shortening of chemotherapy after hCG normalization.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11